These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 39185318)

  • 1. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.
    Zhao J; Tao Y
    Front Pharmacol; 2024; 15():1393940. PubMed ID: 39185318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An observational study on the safety of teprotumumab based on FAERS database.
    Wang XL; Xu SS; Zhou JB; Song ZH
    Endocrine; 2024 Jul; 85(1):313-320. PubMed ID: 38760615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
    Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
    [No Abstract]   [Full Text] [Related]  

  • 9. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
    Wei W; Huang L; Bai Y; Chang E; Liu J
    Front Pharmacol; 2024; 15():1391003. PubMed ID: 39050747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-marketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.
    Huang J; Su A; Yang J; Zhuang W; Li Z
    J Clin Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38878281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.
    Dai Z; Wang G; Zhang J; Zhao Q; Jiang L
    Heliyon; 2024 Jul; 10(13):e33417. PubMed ID: 39027557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
    Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q
    Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.
    Sun W; Li Y; Xia B; Chen J; Liu Y; Pang J; Liu F; Cheng H
    Front Pharmacol; 2023; 14():1257282. PubMed ID: 38264523
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database.
    He B; Zheng W
    Heliyon; 2024 Oct; 10(19):e38450. PubMed ID: 39391518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
    Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system.
    Xia C; Liu Z; Liu J; Lin L; Chen M
    Invest New Drugs; 2024 Aug; ():. PubMed ID: 39133357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.